Intravenous Administration
Intravenous Administration - Related Videos
12:09
Methods for Intravenous Self Administration in a Mouse Model
0 Views •
Cited by 35 •
2012
The intravenous self-administration (IVSA) paradigm is considered to be the gold standard in examining the reinforcing properties of drugs of abuse in rodents. This manuscript outlines the experimental procedures and surgical techniques necessary to obtain reliable IVSA data. In particular, meticulous catheter implantation and maintenance are highlighted.
09:16
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
0 Views •
Cited by 5 •
2016
This article describes the delivery of intracranial electrical stimulation that is temporally and spatially separate from the drug-use environment for the treatment of IV methamphetamine dependence.
07:22
Discontinuing Intravenous Fluids and a Peripheral Intravenous Line
0 Views •
2023
Source: Madeline Lassche, MSNEd, RN and Katie Baraki, MSN, RN, College of Nursing, University of Utah, UT Intravenous (IV) fluid administration and peripheral IV catheters (PIVs) may be discontinued for a number of reasons. The most common reason for discontinuing IV fluids is that the patient has returned to normal body fluid volume (euvolemia) and is able to maintain adequate oral fluid intake or is being discharged from the hospital. In addition, the Centers for Disease Control Guidelines...
02:29
Intravenous Administration of Therapeutic Nanoparticles in a Murine Glioblastoma Model
0 Views •
2025
Source: Kim, B. D., et al. Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model. J. Vis. Exp. (2024)This video demonstrates the intravenous injection of therapeutic nanoparticles in a glioblastoma-bearing mouse. The method enables targeted delivery across the blood-brain barrier and supports non-invasive imaging for evaluating nanoparticle biodistribution and therapeutic efficacy in brain tumors.
09:29
Self-administration Studies
0 Views •
2023
Behavioral reinforcement induced by the rewarding feelings following substance use sometimes leads to addiction, which is demonstrated by increased self-administration. Drug self-administration studies in rodents model human behavior during drug abuse. These models are useful in understanding the neurobiological behavior of addiction in order to help scientists discover new treatments for drug dependence. This video reviews the concepts underlying self-administration studies. A general...
FAQs
Bolus delivery provides a discrete administration, whereas continuous infusion extends delivery over time. This distinction lets clinicians and researchers select an exposure pattern suited to the intended use while retaining control over systemic entry. In infection or immunology studies, the choice can affect how treatment responses are evaluated.
Adjusting dose, rate, and volume regulates systemic exposure rather than treating these settings as interchangeable. Dose determines the amount delivered, while rate and volume shape how administration is controlled over the delivery period. Precise adjustment is especially relevant when experiments require reproducible therapeutic exposure or when clinicians monitor responses during treatment.
Direct access to the bloodstream makes the route valuable when reliable distribution is important. In immunology and infection, this supports administration of antimicrobials, antibodies, and immune-modulating therapies, allowing their systemic exposure to be controlled. It therefore provides a practical framework for examining how treatment changes clinical or experimental responses.
The basic setup uses either a needle or a catheter, followed by delivery as a bolus or continuous infusion. During administration, dose, rate, and volume can be adjusted to regulate exposure. This flexible combination of access device and delivery pattern allows the same route to support different therapeutic or experimental requirements.
Intravenous administration can carry fluids, biologics, diagnostic agents, antimicrobials, antibodies, and immune-modulating therapies. This breadth matters because the route can support both treatment and diagnostic work, while giving researchers a common way to control systemic exposure across different agent types. Replacement fluids are also relevant when severe disease requires supportive delivery.
Researchers turn to this route when an experiment requires precise control over therapeutic exposure or when treatment responses must be evaluated under defined delivery conditions. In severe disease, it also supports rapid, reliable distribution of therapies and replacement fluids. These uses connect administration choices with both experimental design and management of infection or immune-related illness.